Dr. Sehgal on the Structure and Manufacturing Process of CAR T Cells

Video

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

There are three structural parts to a CAR T cell: the ligand which binds to the target on the surface of the B-cell lymphoma, the transmembrane domain, and stimulatory molecules, says Sehgal. Two aspects go into the stimulatory molecules, including CD3 zeta, which is part of the T-cell receptor as well as a costimulatory domain, which can vary between the CD28 and 4-1BB products, she adds.

Regarding the manufacturing process, eligible patients will undergo 1 day of leukapheresis so that their T cells can be collected. Patients do not have to undergo mobilization ahead of time, which differs from the protocol for stem cell transplant. After the T cells have been collected, they are sent to the manufacturing center for a time period of approximately 2 to 4 weeks, explains Sehgal. Once the T cells have been grown sufficiently, the patient comes in to the hospital and receives 3 days of chemotherapy prior to receiving their transfusion anywhere from 2 to 7 days later.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.